Childhood/AYA Cancer

Genetic Precursors to Pediatric Rhabdomyosarcoma Identified

January 07, 2021

“But our study is pointing to new genes to consider. For example, we found that the BRCA2 gene, typically associated with adult breast and ovarian cancer, may also somehow influence the susceptibility of pediatric RMS.”

FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

December 02, 2020

The FDA approved pralsetinib (Gavreto) for adults and children aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who need systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.

FDA Approves Naxitamab-gqgk for Pediatric and Adult High-Risk Neuroblastoma

November 26, 2020

The FDA has granted an accelerated approval to naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

Pediatric Osteosarcoma and Pathogenic TP53 Variants

October 19, 2020

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma, according to findings from the Children’s Oncology Group that were published in JCO Precision Oncology.